{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:06:23Z","timestamp":1790777183772,"version":"4.1.0"},"reference-count":48,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.2967\/jnumed.123.265418","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T17:20:39Z","timestamp":1697736039000},"page":"1956-1964","source":"Crossref","is-referenced-by-count":20,"title":["Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy"],"prefix":"10.2967","volume":"64","author":[{"given":"Clara Diaz","family":"Garcia-Prada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na","family":"Carmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Atis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Parach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Bertolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Poty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Suarez","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook-Geun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Du Manoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schuemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tillement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Constanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"2023120108101136000_64.12.1956.1","unstructured":"Key Statistics for ovarian cancer. American Cancer Society website. https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html. Revised January 12, 2023. Accessed September 11, 2023."},{"key":"2023120108101136000_64.12.1956.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"2023120108101136000_64.12.1956.3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0007"},{"key":"2023120108101136000_64.12.1956.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"2023120108101136000_64.12.1956.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00086-8"},{"key":"2023120108101136000_64.12.1956.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"2023120108101136000_64.12.1956.7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/gcc.22935","article-title":"PARP inhibitors in ovarian cancer: an overview of the practice-changing trials","volume":"60","author":"Foo","year":"2021","journal-title":"Genes Chromosomes Cancer."},{"key":"2023120108101136000_64.12.1956.8","doi-asserted-by":"crossref","first-page":"37061","DOI":"10.18632\/oncotarget.15715","article-title":"The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells","volume":"8","author":"Estupina","year":"2017","journal-title":"Oncotarget."},{"key":"2023120108101136000_64.12.1956.9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4161\/mabs.29316","article-title":"The human M\u00fcllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer","volume":"6","author":"Kersual","year":"2014","journal-title":"MAbs."},{"key":"2023120108101136000_64.12.1956.10","first-page":"12","article-title":"Introduction to radiobiology of targeted radionuclide therapy","volume":"2","author":"Pouget","year":"2015","journal-title":"Front Med (Lausanne)."},{"key":"2023120108101136000_64.12.1956.11","doi-asserted-by":"crossref","first-page":"692436","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"2023120108101136000_64.12.1956.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.107540"},{"key":"2023120108101136000_64.12.1956.13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-010-1639-2","article-title":"177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi","volume":"38","author":"Seidl","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023120108101136000_64.12.1956.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.086819"},{"key":"2023120108101136000_64.12.1956.15","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20050271"},{"key":"2023120108101136000_64.12.1956.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph5010001","article-title":"Pre-clinical assessment of 177Lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease","volume":"5","author":"Ray","year":"2011","journal-title":"Pharmaceuticals (Basel)."},{"key":"2023120108101136000_64.12.1956.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170423"},{"key":"2023120108101136000_64.12.1956.18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13550-017-0283-2","article-title":"Therapeutic efficacy of \u03b1-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model","volume":"7","author":"Gustafsson-Lutz","year":"2017","journal-title":"EJNMMI Res."},{"key":"2023120108101136000_64.12.1956.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178327"},{"key":"2023120108101136000_64.12.1956.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.208611"},{"key":"2023120108101136000_64.12.1956.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.080226"},{"key":"2023120108101136000_64.12.1956.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1486"},{"key":"2023120108101136000_64.12.1956.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.5973"},{"key":"2023120108101136000_64.12.1956.24","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1200\/JCO.1987.5.12.1890","article-title":"Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies","volume":"5","author":"Epenetos","year":"1987","journal-title":"J Clin Oncol."},{"key":"2023120108101136000_64.12.1956.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0985"},{"key":"2023120108101136000_64.12.1956.26","first-page":"953","article-title":"Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity","volume":"5","author":"Rosenblum","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2023120108101136000_64.12.1956.27","first-page":"2806","article-title":"A phase I study of combined modality 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer","volume":"8","author":"Alvarez","year":"2002","journal-title":"Clin Cancer Res."},{"key":"2023120108101136000_64.12.1956.28","first-page":"3249s","article-title":"A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma","volume":"5","author":"Mah\u00e9","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2023120108101136000_64.12.1956.29","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.34"},{"key":"2023120108101136000_64.12.1956.30","doi-asserted-by":"crossref","first-page":"e69613","DOI":"10.1371\/journal.pone.0069613","article-title":"Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb","volume":"8","author":"Boudousq","year":"2013","journal-title":"PLoS One."},{"key":"2023120108101136000_64.12.1956.31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1874471013666201201102056","article-title":"Calcium carbonate microparticles as carriers of 224Ra: impact of specific activity in mice with intraperitoneal ovarian cancer","volume":"14","author":"Li","year":"2021","journal-title":"Curr Radiopharm."},{"key":"2023120108101136000_64.12.1956.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263349"},{"key":"2023120108101136000_64.12.1956.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243394"},{"key":"2023120108101136000_64.12.1956.34","first-page":"20180365","article-title":"AGuIX\u00ae from bench to bedside: transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine","volume":"92","author":"Lux","year":"2019","journal-title":"Br J Radiol."},{"key":"2023120108101136000_64.12.1956.35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","article-title":"Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)","volume":"160","author":"Verry","year":"2021","journal-title":"Radiother Oncol."},{"key":"2023120108101136000_64.12.1956.36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay5279"},{"key":"2023120108101136000_64.12.1956.37","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.5.13054"},{"key":"2023120108101136000_64.12.1956.38","doi-asserted-by":"crossref","first-page":"e103070","DOI":"10.1371\/journal.pone.0103070","article-title":"177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice","volume":"9","author":"Repetto-Llamazares","year":"2014","journal-title":"PLoS ONE."},{"key":"2023120108101136000_64.12.1956.39","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41375-019-0677-4","article-title":"The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2\/M cell cycle arrest","volume":"34","author":"Pichard","year":"2020","journal-title":"Leukemia."},{"key":"2023120108101136000_64.12.1956.40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09553002.2021.1955999","article-title":"Rapid communication: insights into the role of extracellular vesicles during Auger radioimmunotherapy","volume":"99","author":"Karam","year":"2023","journal-title":"Int J Radiat Biol."},{"key":"2023120108101136000_64.12.1956.41","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3390\/pharmaceutics14040814","article-title":"A new generation of ultrasmall nanoparticles inducing sensitization to irradiation and copper depletion to overcome radioresistant and invasive cancers","volume":"14","author":"Rocchi","year":"2022","journal-title":"Pharmaceutics."},{"key":"2023120108101136000_64.12.1956.42","first-page":"137","volume-title":"Methods Cell Biol.","volume":"174","author":"Constanzo","year":"2023"},{"key":"2023120108101136000_64.12.1956.43","first-page":"e0180940","volume-title":"PLOS ONE","volume":"12","author":"Naumann","year":"2017"},{"key":"2023120108101136000_64.12.1956.44","doi-asserted-by":"crossref","first-page":"699822","DOI":"10.3389\/fpubh.2021.699822","article-title":"Radiosensitization effect of gold nanoparticles in proton therapy","volume":"9","author":"Cunningham","year":"2021","journal-title":"Front Public Health."},{"key":"2023120108101136000_64.12.1956.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-7348.1939.tb06990.x"},{"key":"2023120108101136000_64.12.1956.46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131037"},{"key":"2023120108101136000_64.12.1956.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263253"},{"key":"2023120108101136000_64.12.1956.48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.069948"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:12:29Z","timestamp":1701447149000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.2967\/jnumed.123.265418"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265418","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}